U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Center for Drug Evaluation and Research (CDER)
  5. Division of Hematologic Malignancies 2 (DHM2)
  1. Center for Drug Evaluation and Research (CDER)

Division of Hematologic Malignancies 2 (DHM2)

The Division of Hematologic Malignancies 2 (DHM2) regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologic Licensing Applications (BLAs) for Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, and other plasma cell malignancies.

Mailing Address

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Hematologic Malignancies 2 (DHM2)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Phone: (301) 796-7550
Fax: (301) 796-9845

Resources For You

Back to Top